Traders sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading hours on Friday. $256.13 million flowed into the stock on the tick-up and $468.91 million flowed out of the stock on the tick-down, for a money net flow of $212.78 million out of the stock. Of all companies tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $3.48 for the day and closed at $191.24
Several equities research analysts recently issued reports on AMGN shares. Citigroup boosted their price objective on Amgen from $204.00 to $210.00 and gave the company a “neutral” rating in a report on Friday, January 4th. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a report on Monday, January 14th. Goldman Sachs Group reiterated a “buy” rating and issued a $232.00 price objective on shares of Amgen in a report on Thursday, January 17th. Oppenheimer set a $224.00 price objective on Amgen and gave the company a “buy” rating in a report on Sunday, January 27th. Finally, Royal Bank of Canada reiterated a “neutral” rating on shares of Amgen in a report on Friday, February 1st. Twelve analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $209.79.
The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36. The firm has a market capitalization of $116.84 billion, a price-to-earnings ratio of 13.28, a PEG ratio of 2.25 and a beta of 1.21.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, January 29th. The medical research company reported $3.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.26 by $0.16. Amgen had a return on equity of 66.74% and a net margin of 35.35%. The company had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $5.88 billion. During the same quarter in the prior year, the business earned $2.89 EPS. On average, analysts forecast that Amgen, Inc. will post 13.97 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 3.03%. Amgen’s dividend payout ratio (DPR) is 40.28%.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total transaction of $377,760.00. Following the sale, the director now owns 14,988 shares in the company, valued at approximately $2,830,933.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.27% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. UNIVEST FINANCIAL Corp boosted its position in shares of Amgen by 1.5% during the 4th quarter. UNIVEST FINANCIAL Corp now owns 23,544 shares of the medical research company’s stock worth $4,583,000 after acquiring an additional 355 shares in the last quarter. Pensionfund DSM Netherlands acquired a new position in shares of Amgen during the 4th quarter worth about $3,738,000. Ferguson Wellman Capital Management Inc. boosted its position in shares of Amgen by 0.6% during the 4th quarter. Ferguson Wellman Capital Management Inc. now owns 208,173 shares of the medical research company’s stock worth $40,525,000 after acquiring an additional 1,253 shares in the last quarter. Congress Asset Management Co. MA boosted its position in shares of Amgen by 0.8% during the 4th quarter. Congress Asset Management Co. MA now owns 40,627 shares of the medical research company’s stock worth $7,909,000 after acquiring an additional 311 shares in the last quarter. Finally, Consolidated Investment Group LLC boosted its position in shares of Amgen by 7.2% during the 4th quarter. Consolidated Investment Group LLC now owns 22,434 shares of the medical research company’s stock worth $4,367,000 after acquiring an additional 1,500 shares in the last quarter. Institutional investors own 78.13% of the company’s stock.
Amgen Company Profile (NASDAQ:AMGN)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: What type of investment options does a Roth IRA provide?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.